Premature Centromere Division of Metaphase Chromosomes in Peripheral Blood Lymphocytes of Alzheimer’s Disease Patients: Relation to Gender and Age

Lada Živković,1 Biljana Spremo-Potparević,1 Bosiljka Plečaš-Solarović,1 Ninoslav Djelić,2 Gordana Ocić,3 Predrag Smiljković,3 Sandra L. Siedlak,4 Mark A. Smith,4 and Vladan Bajić5

1Institute of Physiology, Department of Biology, Faculty of Pharmacy and 2Department of Biology, Faculty of Veterinary Medicine, University of Belgrade, Serbia.
3Institute of Neurology, Clinical Centre of Serbia, Belgrade.
4Department of Pathology, Case Western Reserve University, Cleveland, Ohio.
5Institute of Biomedical Research, Galenika a.d., Belgrade, Serbia.

Address correspondence to Lada Živković, MSc, Institute of Physiology, Department of Biology, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia. Email: lada@pharmacy.bg.ac.rs

Chromosomal alterations are a feature of both aging and Alzheimer’s disease (AD). This study examined if premature centromere division (PCD), a chromosomal instability indicator increased in AD, is correlated with aging or, instead, represents a de novo chromosomal alteration due to accelerating aging in AD. PCD in peripheral blood lymphocytes was determined in sporadic AD patients and gender and age-matched unaffected controls. Metaphase nuclei were analyzed for chromosomes showing PCD, X chromosomes with PCD (PCD,X), and acrocentric chromosomes showing PCD. AD patients, regardless of age, demonstrated increased PCD on any chromosome and PCD on acrocentric chromosomes in both genders, whereas an increase in frequency of PCD,X was expressed only in women. This cytogenetic analysis suggests that PCD is a feature of AD, rather than an epiphenomenon of chronological aging, and may be useful as a physiological biomarker that can be used for disease diagnosis.

Key Words: Age—Chromosome—Premature centromere division—Sporadic Alzheimer’s disease.

Received April 1, 2010; Accepted July 26, 2010

Decision Editor: Rafael de Cabo, PhD

Alzheimer’s disease (AD), the most common cause of dementia in late life, is multifactorial with several genetic factors and environmental exposures playing a role in its etiology (1) and pathogenesis (2–4). AD occurs as a familial form in a small number of cases in which a clear pattern of inheritance exists (5). The sporadic form of AD (SAD), however, is far more common, representing 90%–95% of all cases. Although the specific etiology of SAD is not clearly understood, aging represents the major risk factor and is coincident with disease development (6). In addition, SAD, as with aging, is associated with alterations in chromosome number and/or structure (7).

Premature centromere division (PCD), a chromosomal alteration, is regarded as a phenomenon manifested as a loss of control of centromere separation and segregation and is characterized by distinctive separation of chromosome chromatids earlier than usual during interphase of mitosis (8–11). Cytogenetic analysis of peripheral blood lymphocytes shows increased aneuploidy and higher levels of PCD in patients with AD compared with controls (11–17). In fact, familial and SAD might be explained by the presence of the mosaic trisomy 21 in later life of normal individuals such that nondisjunction may underlie both AD and Down’s syndrome (18). In this regard, compared with elderly controls, AD participants have a higher frequency of aneuploidy of chromosome 21 as well as chromosome 13 in peripheral blood lymphocytes (15). Aside from chromosome 21, based on the known unequal gender distribution, the most intriguing chromosomal abnormalities in AD patients are the sex chromosomes, which also show aneuploidy in the course of aging (19–21).

Given the overlap in abnormalities between normal aging and AD, the goal of this study was to examine the incidence of PCD of metaphase chromosomes in peripheral blood lymphocytes and not only greatly expand upon previous studies, thereby allowing gender and age comparisons of SAD patients with healthy controls, but also, for the first time, directly and simultaneously compare PCD in three separate chromosomes. Specifically, we assessed (a) the number of metaphases with at least one chromosome showing PCD (PCD,C), (b) the number of metaphases with at least one X chromosome showing PCD (PCD,X), and (c) the number of metaphases with at least one acrocentric chromosome showing PCD phenomenon (PCD,A). Our data clearly indicate that the PCD phenomenon in SAD patients is not simply a consequence of chronological aging.
but rather represents a more specific process linked to the etiology and/or pathogenesis of the disease process.

**Materials and Methods**

**Participants**

Blood samples were collected by venous puncture from SAD patients and age-matched control participants. Probable AD was diagnosed clinically and met the criteria of the National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease Association (22). Because of familial history, all patients were classified as sporadic cases. The AD patients comprised 13 females (ages 53–80 years; mean $\pm$ SEM $= 69.3 \pm 2.6$ years) and 11 males (ages 60–81 years; mean $\pm$ SEM $= 68.2 \pm 1.7$ years) and control patients comprised 13 females (ages 55–83 years; mean $\pm$ SEM $= 68.9 \pm 2.8$ years) and 11 male volunteers (ages 58–80 years; mean $\pm$ SEM $= 68.8 \pm 2.0$ years) and were in general good health and without a history of neurological and/or psychiatric disorders. The ethical committee of the Medical School at the University of Belgrade approved the study, and written informed consent was obtained from all participants or from their families.

**Blood Culture**

Peripheral blood lymphocyte culture stimulations, cell harvests, and slide preparations were performed as previously described (23). Briefly, heparinized whole blood samples (0.8 mL) were added to vials with 9.2 mL RPMI 1640 medium (Gibco, Grand Island, NY), supplemented with 10% fetal calf serum (Gibco, Eggenstein, Germany), 5 $\mu$g/mL phytohemagglutinin (Inep-Zemun, Serbia), and a 1% cocktail of antibiotics penicillin/streptomycin (Bio Whifa-her, Barcelona, Spain). Cultures were incubated at 37°C for 72 hours, and 2 hours before cultures were harvested, 0.05 $\mu$g/mL colcemid (Ciba, Basel, Switzerland) was added to the media. Cells were treated with hypotonic solution (20 minutes), fixed in 3:1 methanol/acetic acid (3 $\times$ 20 minute), then placed on clean grease-free chilled glass slides, and air dried over a flame. The slides were aged for the next 5–7 days and then stained using the G-banding technique (24) to identify and verify PCD of chromosomes.

**PCD Counting**

Slides were examined using Olympus BX 50 microscope (Olympus Optical Co., GmbH, Hamburg, Germany) under oil immersion. For each sample, 100 cells at metaphase were analyzed. The following parameters were recorded: the number of metaphases with at least one PCD chromosome (PCD,C), the number of metaphases with at least one X chromosome showing PCD (PCD,X), and metaphases containing at least one acrocentric chromosome with PCD (PCD,A).

**Data Analysis and Statistics**

The data are presented as group means $\pm$ SEM. The impact of two factors (disease and gender) and their interaction on the frequency of PCD were compared by the multivariate general linear model. When the $F$ value was significant, the comparisons between groups were done by the nonparametric Mann–Whitney test because the Levene’s test for equality of variances revealed that some groups of data did not come from populations with the same variance. The correlation between PCD frequency and age was also tested in both AD and control patients by the Spearman’s nonparametric correlation. $p$ values of $<0.05$ were considered significant. Statistical software SPSS for Windows (Version 7.5) was used.
RESULTS

Statistical analysis revealed that the diagnosis of AD significantly affected the frequency of PCD, C; PCD, X; and PCD, A. Gender, however, influenced the frequency of PCD, C and PCD, X but not PCD, A. On the other hand, interaction of gender and disease was only expressed in PCD, X frequency (Table 1).

Post hoc comparisons between corresponding groups showed that in women, those with a diagnosis of AD had a markedly and significantly increased frequency of PCD, C (Figure 1A), PCD, X (Figure 1B), and PCD, A (Figure 1C) in comparison with control group. In male patients with AD, the frequencies of PCD, C (Figure 1A) and PCD, A (Figure 1C) were significantly greater than in corresponding controls. No difference was found in the percentage of PCD, X in males patients (Figure 1B). Importantly, in the sampled population of female individuals aged 53–80 years old, neither the AD cases nor the control cases showed any statistically significant correlation between the frequency of PCD and age (Figure 2). Similarly, in the sampled population of male individuals aged 58–81 years old, the frequency of PCD, C; PCD, X; and PCD, A did not significantly correlate with age in either the AD or the control cohorts (Figure 2).

Furthermore, our results demonstrated that in control patients, PCD, C and PCD, X were significantly more frequent in women than in men (Figure 1A and B). These gender differences were expressed in both AD and control patients. However, the frequency of acrocentrics was similar both in control and AD groups of different genders (Figure 1C). Representative chromosomes analyzed are shown in Figure 3.

DISCUSSION

In this study, the frequency of PCD in peripheral blood lymphocytes was determined in male and female clinical patients diagnosed with SAD and compared with age-matched control patients. Replication, separation, and segregation of human chromosomes are highly controlled processes through the cell cycle. PCD, as a cause of improper chromosome separation, is found to be increased in patients with AD.
Infact, lossofcontrolofthechromosome separation maybe regarded asamanifestationofchromosome instability (25).

In this work, using cases carefullychosenspanning53–83years old, PCD was notfoundtocorrelatewithageafterthesixthdecadeoflife.

A classicstudyevaluatedPCD inbothyoung and agednormalwomenandcomparedtheper-
centageofmetaphasecellsexhibitingPCD. Inwomenaged22–39years, PDoccurredlessthan1%ofthetime, women aged40–59years old showedanaverageof2.5%PCD, and aged women of 60–89 years had an averagePCD occur-
renceof4%(26). Thedatainthepresentworkfoundsimilar
valuesfortheadvancedagecontrolindividualsandimpor-
tantlyfoundthataftertheageof53years, PCDnolonger
increasesignificantlywithadvancingagewithinanygroup
of male or female agedornormalpeople. Yet, ourresults do
demonstrate that AD patients, regardless of age, have sig-
nificantly increased incidence of PCD in peripheral blood
lymphocytes both in male and in female participants.

Our analysis of three separate PCD events (PCD,C; PCD,X; and PCD,A) showed that the principal gender-
related difference was in the frequency of PCD,X, which was
only increased in female AD patients. Because AD affects
twice as many women as men (27), this finding may have
important pathological implications. Indeed, in AD, the X
chromosome frequently shows aneuploidy and PCD phe-
omenon (19–21), and gender clearly plays an important
role in the pathogenesis of AD, influencing the risk of de-
veloping AD (28–30). One possible explanation for this
gender-related difference in PCD,X is the finding that par-
tially inactive X chromosomes in lymphocytes from elderly
women are more susceptible to PCD (19,31,32). Consistent
with this, X chromosome analysis by fluorescence in situ hy-
bridization of peripheral blood lymphocytes revealed a higher
percentage of PCD in female AD patients than in corre-
ponding controls (11,13). Additionally, PCD,X occursmuch
earlier than the metaphase of mitosis, that is, in interphase of
the cell cycle, immediately after DNA replication (11).
PCD,X has also been detected in the interphase nuclei of
neurons in the frontal cerebral cortex in SAD females (13).

In acrocentrics (chromosomes 21,13,14,15, and 22), PCD is markedlyincreasedboth in female and in male AD
patients compared with corresponding controls. Such a re-
sult is not surprising because aneuploidy of chromosomes
21 and 13 is well established in AD patients (15,33). In fact,
bothfamilial and SAD can be explained by the presence of the
mosaic trisomy of chromosome 21, and given this, it is
likely not coincidental that patients with Down syndrome
(i.e., trisomy 21) invariably develop the pathological and
clinical characteristics of AD (16,18,34,35). In AD patients,
aeuploidy of chromosome 21 is more frequent than that of
chromosome 13 (15). Although the molecular mechanisms
of chromosome instability are still not fully understood, in
relation to AD, it is known that mutations in the presenilin 1
gene lead to abnormal presenilin function giving rise to de-
fect in the cell cycle, increased number of abnormal mitotic
spindles, and improper chromosome segregation (33).

It is well known that there is a sequential segregation of
replicated genetic material in normal mammalian cells (36–
40). Between the end of replication and the moment when
segregation of replicated genetic material begins in the
mitotic anaphase, two sister chromatids are tightly held
together in the centromere region (41). In humans, the centromeres of chromosomes 2, 8, 17, and 18 separate earliest, whereas chromosomes 13, 14, 15, 21, and 22 are among the last to split into two subunits (42,43). In addition, chromosomes from D and G group participate in satellite association. PCD of acrocentric chromosomes are connected with aneuploidy, such as that occurs on chromosome 21 in Roberts syndrome (44), in chronic myelogenous leukemia (42), and in AD (15). In fact, increased aneuploidy and PCD may account for increased hybridization (fluorescence in situ hybridization) spots in neurons in AD compared with controls (21), although a defective ectopic cell cycle reentry cannot be discounted (45,46).

Advanced age is the major contributing factor for increased risk of developing AD (47,48). Beyond the age of 65 years, every 5 years represents a doubling of the risk for the development of AD such that more than 30% of individuals aged 80 years and older are affected (49–51). Although PCD does increase between the ages of 20 and 60 years (26), the present work found no effect of age on the PCD frequency in the lymphocytes of either AD patients or control patients after the age of 53 years. Other factors such as oxidative stress that also are increased early in the development of AD (52) and are found to be increased, decades before disease onset, undoubtedly contribute to the disease (53). Chromosome stability alterations, therefore, likely occur a number of years prior to clinical diagnosis of AD, a supposition consistent with the hypothesis that both genetic and SAD may be predicted by certain chromosome alterations in apparently normal individuals (34). Additionally, PCD might also prove useful as cytogenetic biomarkers for the diagnosis of AD or to monitor progression of the disease. As a noninvasive method using blood samples, this assay could be adapted as a screening tool for predicting disease. Current thoughts on the use of biomarkers for identifying patients at risk for developing AD stress the fact that any single biomarker is not reliable. However, the combination of biomarkers with genetic, cognitive, and imaging analyses may be valid (54). PCD assays would fill another niche in the broad range of measurements necessary for adequate biomarker development and future clinical use.

Although aging per se is associated with chromosome abnormalities (19,20,55), a noticeable difference between lymphocyte PCD frequency in AD patients and their age-matched controls certainly questions the notion that cytogenetic alterations are inherent to the cellular aging process but are in fact specifically related to AD (55,56). In fact, we would suggest that our data show that PCD and chromosome centromere instability in AD are distinct from an epiphenomenon of the aging process and in fact likely are etiological and pathologic contributors to the disease phenotype (3,4).

**FUNDING**

The work was supported by the Serbian Ministry of Science (grant #143018) and by the National Institutes of Health (AG028679 and AG031364).

**REFERENCES**